{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T04:23:30Z","timestamp":1773980610116,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"FCT \u2013 Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["UIDB\/04728\/2020"],"award-info":[{"award-number":["UIDB\/04728\/2020"]}]},{"DOI":"10.13039\/501100005774","name":"Universitat de Barcelona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study assessed the effectiveness of the 0.19-mg fluocinolone acetonide (FAc) implant by multimodal measurements in patients with non-infectious uveitis (NIU) in a real-world setting in Spain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective study of patients who had NIU including uveitic macular oedema (UME) with\u2009\u2265\u200912\u00a0months follow-up was done. Exclusion criteria include infectious uveitis and uncontrolled glaucoma or ocular hypertension requiring more than 2 medications. Effectiveness was assessed using a multicomponent outcome measure that included nine outcomes. Effectiveness was defined as all components being met at every timepoint. Secondary outcome measures were onset or progression of glaucoma and investigator-reported adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-six eyes from 22 patients were included, with 96.2% having an indication including UME. During the 12-month study, the FAc implant was effective in 15 (57.7%) eyes, reaching effectiveness as soon as 2\u00a0weeks post-implantation. Mean best-corrected visual acuity and mean central macular thickness (CMT) were significantly improved vs. baseline at all timepoints (all comparisons\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). During the 12-month study, inflammation markers (anterior chamber cells and vitreous haze) had also significantly declined. Factors predicting effectiveness at month 12 were systemic corticosteroid dose pre-FAc, higher immunomodulatory therapy (IMT) load at baseline and thicker retinal nerve fibre layer (RNFL) at baseline (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Factors predicting failure were male gender, thinner RNFL at baseline and treatment ineffectiveness at 1\u00a0month (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). In parallel, corticosteroid and IMT use also declined significantly. No significant increase in IOP was detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The FAc implant is safe and effective at treating NIU over 12\u00a0months in a real-world setting in Spain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10792-023-02828-6","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T06:02:50Z","timestamp":1694498570000},"page":"4181-4195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Intravitreal fluocinolone acetonide 0.19\u00a0mg (ILUVIEN\u00ae) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12\u00a0months"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4753-2111","authenticated-orcid":false,"given":"Aina","family":"Moll-Udina","sequence":"first","affiliation":[]},{"given":"In\u00e9s","family":"Hernanz","sequence":"additional","affiliation":[]},{"given":"Maite","family":"Sainz-de-la-Maza","sequence":"additional","affiliation":[]},{"given":"Laura","family":"Pelegr\u00edn","sequence":"additional","affiliation":[]},{"given":"Ana Isabel","family":"Coelho-Borges","sequence":"additional","affiliation":[]},{"given":"Marta","family":"Pazos","sequence":"additional","affiliation":[]},{"given":"Alfredo","family":"Ad\u00e1n","sequence":"additional","affiliation":[]},{"given":"Victor","family":"Lloren\u00e7","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"2828_CR1","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/J.PRETEYERES.2011.06.005","volume":"30","author":"MD de Smet","year":"2011","unstructured":"de Smet MD, Taylor SRJ, Bodaghi B et al (2011) Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 30:452\u2013470. https:\/\/doi.org\/10.1016\/J.PRETEYERES.2011.06.005","journal-title":"Prog Retin Eye Res"},{"key":"2828_CR2","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1111\/AOS.12987","volume":"94","author":"JE Thorne","year":"2016","unstructured":"Thorne JE, Skup M, Tundia N et al (2016) Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis. Acta Ophthalmol 94:e331\u2013e339. https:\/\/doi.org\/10.1111\/AOS.12987","journal-title":"Acta Ophthalmol"},{"key":"2828_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/09273948.2019.1576910","volume":"27","author":"M Accorinti","year":"2019","unstructured":"Accorinti M, Okada AA, Smith JR, Gilardi M (2019) Epidemiology of macular edema in Uveitis. Ocul Immunol Inflamm 27:169\u2013180. https:\/\/doi.org\/10.1080\/09273948.2019.1576910","journal-title":"Ocul Immunol Inflamm"},{"key":"2828_CR4","doi-asserted-by":"publisher","DOI":"10.1080\/17469899.2019.1644168","author":"A Ad\u00e1n","year":"2019","unstructured":"Ad\u00e1n A, Moll-Udina A, Alba-Linero C et al (2019) Recent progress in the treatment of uveitic macular edema. Expert Rev Ophthalmol. https:\/\/doi.org\/10.1080\/17469899.2019.1644168","journal-title":"Expert Rev Ophthalmol"},{"key":"2828_CR5","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1016\/J.OPHTHA.2015.07.036","volume":"122","author":"O Tomkins-Netzer","year":"2015","unstructured":"Tomkins-Netzer O, Lightman S, Drye L et al (2015) Outcome of treatment of uveitic macular edema: the multicenter uveitis steroid treatment trial 2-year results. Ophthalmology 122:2351\u20132359. https:\/\/doi.org\/10.1016\/J.OPHTHA.2015.07.036","journal-title":"Ophthalmology"},{"key":"2828_CR6","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/EYE.2016.133","volume":"30","author":"RS Grajewski","year":"2016","unstructured":"Grajewski RS, Boelke AC, Adler W et al (2016) Spectral-domain optical coherence tomography findings of the macula in 500 consecutive patients with uveitis. Eye (Lond) 30:1415\u20131423. https:\/\/doi.org\/10.1038\/EYE.2016.133","journal-title":"Eye (Lond)"},{"key":"2828_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0B013E31829F7415","volume":"34","author":"MM Yang","year":"2014","unstructured":"Yang MM, Lai TYY, Luk FOJ, Pang CP (2014) The roles of genetic factors in uveitis and their clinical significance. Retina 34:1\u201311. https:\/\/doi.org\/10.1097\/IAE.0B013E31829F7415","journal-title":"Retina"},{"key":"2828_CR8","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1517\/14712598.2014.956074","volume":"14","author":"U Pleyer","year":"2014","unstructured":"Pleyer U, St\u00fcbiger N (2014) New pharmacotherapy options for noninfectious posterior uveitis. Expert Opin Biol Ther 14:1783\u20131799. https:\/\/doi.org\/10.1517\/14712598.2014.956074","journal-title":"Expert Opin Biol Ther"},{"key":"2828_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/S40135-016-0090-3","volume":"4","author":"R Goldhardt","year":"2016","unstructured":"Goldhardt R, Rosen BS (2016) Uveitic macular edema: treatment update. Curr Ophthalmol Rep 4:30\u201337. https:\/\/doi.org\/10.1007\/S40135-016-0090-3","journal-title":"Curr Ophthalmol Rep"},{"issue":"Suppl 1","key":"2828_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000318021","volume":"224","author":"SRJ Taylor","year":"2010","unstructured":"Taylor SRJ, Isa H, Joshi L, Lightman S (2010) New developments in corticosteroid therapy for uveitis. Ophthalmologica 224(Suppl 1):46\u201353. https:\/\/doi.org\/10.1159\/000318021","journal-title":"Ophthalmologica"},{"key":"2828_CR11","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1016\/j.ophtha.2014.05.021","volume":"121","author":"HN Sen","year":"2014","unstructured":"Sen HN, Vitale S, Gangaputra SS et al (2014) Periocular corticosteroid injections in uveitis: effects and complications. Ophthalmology 121:2275\u20132286. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.021","journal-title":"Ophthalmology"},{"key":"2828_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","volume":"126","author":"JE Thorne","year":"2019","unstructured":"Thorne JE, Sugar EA, Holbrook JT et al (2019) Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of Uveitic macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology 126:283\u2013295. https:\/\/doi.org\/10.1016\/j.ophtha.2018.08.021","journal-title":"Ophthalmology"},{"key":"2828_CR13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","volume":"130","author":"DA Jabs","year":"2000","unstructured":"Jabs DA, Rosenbaum JT, Foster CS et al (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130:492\u2013513. https:\/\/doi.org\/10.1016\/S0002-9394(00)00659-0","journal-title":"Am J Ophthalmol"},{"key":"2828_CR14","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/j.ophtha.2017.06.017","volume":"124","author":"EB Suhler","year":"2017","unstructured":"Suhler EB, Thorne JE, Mittal M et al (2017) Corticosteroid-related adverse events systematically increase with corticosteroid dose in noninfectious intermediate, posterior, or Panuveitis: Post Hoc analyses from the VISUAL-1 and VISUAL-2 trials. Ophthalmology 124:1799\u20131807. https:\/\/doi.org\/10.1016\/j.ophtha.2017.06.017","journal-title":"Ophthalmology"},{"key":"2828_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","volume":"129","author":"C Lowder","year":"2011","unstructured":"Lowder C, Belfort R, Lightman S et al (2011) Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 129:545\u2013553. https:\/\/doi.org\/10.1001\/archophthalmol.2010.339","journal-title":"Arch Ophthalmol"},{"key":"2828_CR16","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2147\/OPTH.S15696","volume":"4","author":"JS Myung","year":"2010","unstructured":"Myung JS, Aaker GD, Kiss S (2010) Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant. Clin Ophthalmol 4:1423\u20131426. https:\/\/doi.org\/10.2147\/OPTH.S15696","journal-title":"Clin Ophthalmol"},{"key":"2828_CR17","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.ajo.2014.09.003","volume":"158","author":"J Zarranz-Ventura","year":"2014","unstructured":"Zarranz-Ventura J, Carre\u00f1o E, Johnston RL et al (2014) Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: Indications, outcomes, and reinjection frequency. Am J Ophthalmol 158:1136-1145.e5. https:\/\/doi.org\/10.1016\/j.ajo.2014.09.003","journal-title":"Am J Ophthalmol"},{"key":"2828_CR18","unstructured":"FDA. Retisert.Prescribinf information (2011) FDA. Retisert. Prescribinf information. 2011. In: 2011. chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021737s019.pdf"},{"key":"2828_CR19","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","volume":"118","author":"JH Kempen","year":"2011","unstructured":"Kempen JH, Altaweel MM, Holbrook JT et al (2011) Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: The multicenter uveitis steroid treatment trial. Ophthalmology 118:1916\u20131926. https:\/\/doi.org\/10.1016\/j.ophtha.2011.07.027","journal-title":"Ophthalmology"},{"key":"2828_CR20","unstructured":"EMEA.ILUVIEN SmPC EMEA.ILUVIEN SmPC. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu3161647"},{"key":"2828_CR21","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/J.OPHTHA.2020.04.001","volume":"127","author":"GJ Jaffe","year":"2020","unstructured":"Jaffe GJ, Pavesio CE (2020) Effect of a Fluocinolone Acetonide insert on recurrence rates in noninfectious intermediate, posterior, or Panuveitis: three-year results. Ophthalmology 127:1395\u20131404. https:\/\/doi.org\/10.1016\/J.OPHTHA.2020.04.001","journal-title":"Ophthalmology"},{"key":"2828_CR22","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT et al (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140:509\u2013516. https:\/\/doi.org\/10.1016\/j.ajo.2005.03.057","journal-title":"Am J Ophthalmol"},{"key":"2828_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","volume":"92","author":"RB Nussenblatt","year":"1985","unstructured":"Nussenblatt RB, Palestine AG, Chan CC, Roberge F (1985) Standardizatlon of vitreal inflammatory activity in intermediate and posterior Uveitis. Ophthalmology 92:467\u2013471. https:\/\/doi.org\/10.1016\/S0161-6420(85)34001-0","journal-title":"Ophthalmology"},{"key":"2828_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.12.034","author":"RB Nussenblatt","year":"2005","unstructured":"Nussenblatt RB, Peterson JS, Foster CS (2005) Initial Evaluation of Subcutaneous Daclizumab Treatments for Noninfectious Uveitis A Multicenter Noncomparative Interventional Case Series. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2004.12.034","journal-title":"Ophthalmology"},{"key":"2828_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/S40123-021-00426-2","volume":"11","author":"M Battista","year":"2022","unstructured":"Battista M, Starace V, Cicinelli MV et al (2022) Efficacy of 0.19 mg Fluocinolone Acetonide implant in non-infectious posterior uveitis evaluated as area under the curve. Ophthalmol Ther 11:215\u2013224. https:\/\/doi.org\/10.1007\/S40123-021-00426-2","journal-title":"Ophthalmol Ther"},{"key":"2828_CR26","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/S00417-021-05504-6","volume":"260","author":"A Studsgaard","year":"2022","unstructured":"Studsgaard A, Clemmensen K\u00d8, Nielsen MS (2022) Intravitreal fluocinolone acetonide 0.19 mg (Iluvien\u00ae) for the treatment of uveitic macular edema: 2-year follow-up of 20 patients. Graefes Arch Clin Exp Ophthalmol 260:1633\u20131639. https:\/\/doi.org\/10.1007\/S00417-021-05504-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2828_CR27","doi-asserted-by":"crossref","unstructured":"Bansal P, Agarwal A, Gupta V, et al (2015) Spectral domain optical coherence tomography changes following intravitreal dexamethasone implant, Ozurdex \u00ae in patients with uveitic cystoid macular edema. In: Indian Journal of Ophthalmology. Medknow, pp 416\u2013422","DOI":"10.4103\/0301-4738.159870"},{"key":"2828_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/JCM10173966","author":"M Hikal","year":"2021","unstructured":"Hikal M, Celik N, Auffarth GU et al (2021) Intravitreal 0.19 mg fluocinolone acetonide implant in non-infectious uveitis. J Clin Med. https:\/\/doi.org\/10.3390\/JCM10173966","journal-title":"J Clin Med"},{"key":"2828_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/S12348-019-0168-9","author":"LF Weber","year":"2019","unstructured":"Weber LF, Marx S, Auffarth GU et al (2019) Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema. J Ophthalmic Inflamm Infect. https:\/\/doi.org\/10.1186\/S12348-019-0168-9","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"2828_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/09273948.2016.1215472","volume":"26","author":"AK Reddy","year":"2018","unstructured":"Reddy AK, Burkholder BM, Khan IR, Thorne JE (2018) Iluvien implantation for uveitis and uveitic macular edema. Ocul Immunol Inflamm 26:315\u2013316. https:\/\/doi.org\/10.1080\/09273948.2016.1215472","journal-title":"Ocul Immunol Inflamm"},{"key":"2828_CR31","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/J.OPHTHA.2014.09.008","volume":"122","author":"DB Moore","year":"2015","unstructured":"Moore DB, Jaffe GJ, Asrani S (2015) Retinal nerve fiber layer thickness measurements: uveitis, a major confounding factor. Ophthalmology 122:511\u2013517. https:\/\/doi.org\/10.1016\/J.OPHTHA.2014.09.008","journal-title":"Ophthalmology"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02828-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-023-02828-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02828-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T07:12:31Z","timestamp":1695625951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-023-02828-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["2828"],"URL":"https:\/\/doi.org\/10.1007\/s10792-023-02828-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2855772\/v1","asserted-by":"object"}]},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]},"assertion":[{"value":"24 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Hospital Clinic of Barcelona (HCB\/0440).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individuals participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}